Loading clinical trials...
Loading clinical trials...
An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma
Conditions
Interventions
KCP-330
Locations
2
United States
Memorial Sloan Kettering Cancer Centre
New York, New York, United States
Princess Margaret Hospital
Toronto, Ontario, Canada
Start Date
July 30, 2013
Primary Completion Date
October 21, 2016
Completion Date
October 21, 2016
Last Updated
January 8, 2024
NCT04704661
NCT05039801
NCT06066138
NCT03715933
NCT07479732
NCT07156565
Lead Sponsor
Karyopharm Therapeutics Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions